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Abstract
Objective and design: Low grade inflammation is of pathogenic importance in atherosclerosis and in the
development of cardiovascular disease (CVD) and type 2 diabetes (T2D). Matrix GLA protein (MGP), an inhibitor of
medial calcification of arteries, is increased in patients with atherosclerosis. In the present study levels of markers of
calcification (MGP) and inflammation (YKL-40, hsCRP) were evaluated in patients with T2 D and/or ischemic heart
disease (IHD).
Materials and methods: The study population consisted of 1) patients with T2D (n = 45); 2) patients with IHD
(n = 37); patients with both T2D and IHD (n = 20) and 4) healthy controls (n = 20). Biochemical parameters were
measured in venous blood samples.
Results: Levels of MGP, YKL-40 and hsCRP were increased in patients with IHD and/or T2D (p < 0.0001) and
patients with T2D and IHD had higher MGP levels (p < 0.001). In multiple linear regression analyses MGP was
associated with patient category (r = 0.36, p < 0.001), and HDL-cholesterol levels (r = 0.29, p < 0.001) adjusting for
the significant covariates.
Conclusions: In patients with T2D and/or IHD we found increased levels of plasma MGP indicative of a
progressing calcification process. This process is paralleled by increased levels of YKL-40 and hsCRP, which most
likely reflect the concomitant low grade inflammatory state in these patients
Introduction
Low grade inflammation and activation of the innate
immune system play a role in the common pathogenesis
of both insulin resistance and endothelial dysfunction
and subsequently the development of type 2 diabetes
(T2D) and atherosclerosis. Several proinflammatory cyto-
kines, acute phase-reactants and cell adhesion molecules
seem to play a role in low grade inflammation, and today
there is substantial evidence supporting the role of
C-reactive protein (CRP), interleukin-6 (IL-6) and tumor
necrosis factor-a (TNFa) among others as cardiovascular
risk markers and participants in the pathogenesis of
obesity, T2D and cardiovascular disease (CVD) [1-4].
CRP still remains the most validated biomarker in this
context, although the substantial knowledge about CRP
as a predictor of cardiovascular events is being supple-
mented by studies on emerging markers [5].
Matrix g-carboxyglutamate (Gla) protein (MGP) is an
extracellular matrix protein with wide tissue distribu-
tion, not only detectable in the normal blood vessels but
also in calcified atherosclerotic plaques [6]. The main
function of MGP is to inhibit medial calcification of
arteries and thereby to protect the normal environment
in the vascular wall [7-9]. Its main sources are cartilage
and the vessel wall where it is synthesized by chondro-
cytes and vascular smooth muscle cells (VSMCs),
respectively [8,10,11]. The importance of MGP to pre-
vent calcification in soft tissues in vivo has been
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calcification of the elastic lamellae in the tunica media
resulted in rupture of the large arteries within 8 weeks
[8]. The function of MGP as an inhibitor of vascular cal-
cification is exercised in the local tissues and no biologi-
cal function of circulating MGP has been demonstrated
[12]. However, serum MGP levels have been found to
be significantly increased in patients with severe athero-
sclerosis and circulating MGP can be regarded as a mar-
ker of atherosclerosis reflecting the degree of inhibition
of ongoing calcification processes in the vascular wall.
This is consistent with the high MGP mRNA expression
observed in atherosclerotic vessels and plaques in
patients with type 1 diabetes [9,13].
YKL-40 is a 40 kDa heparin- and chitin-binding glyco-
protein which is secreted in vitro by a variety of cells.
In vivo YKL-40 is found in subpopulations of macro-
phages and VSMCs in different tissues with inflamma-
tion and extracellular matrix remodeling as in
atherosclerotic plaques [14,15]. YKL-40 induces matura-
tion of monocytes to macrophages and is secreted by
macrophages during late stages of differentiation and by
activated macrophages [14,15]. YKL-40 has also been
shown to be an adhesion and migration factor for vascular
cells and it is secernated by differentiated VSMCs [14,15].
The aim of the present study was to evaluate levels of
markers of calcification (MGP) and inflammation (YKL-
40, hsCRP) in patients with T2D and/or ischemic heart
disease (IHD) and in healthy control subjects.
Materials and methods
Study population
The study population consisted of 1) patients with T2D (n
= 45); 2) patients with IHD (n = 37); patients with both
T2D and IHD (n = 20) and 4) healthy glucose tolerant
controls (n = 20). Patients with T2D, but without IHD,
were all without clinical or biochemical signs of diabetic
complications. The patients with T2D were all on oral
anti-hyperglycemic treatment, none received insulin. All
healthy control subjects were Caucasian and had a seden-
tary lifestyle, and did not take any medication. Individuals
with inflammatory conditions such as ongoing infectious
disease/use of antibiotics, rheumatic or connective tissue
disorders were excluded from the study. Furthermore,
individuals with known chronic obstructive pulmonary
disease, kidney disease or cancer were also excluded,
because levels of YKL-40 are known to be increased in
these conditions [14]. The study was approved by the local
ethics committee (H-B-2007-058) and investigations con-
formed to the principles of The Helsinki Declaration.
Clinical data
All participants underwent a clinical examination including
an ECG. A medical history was obtained and medications
were recorded. The following baseline characteristics were
also registered: known prior myocardial infarction (MI)
and/or previous coronary revascularization procedures
(percutaneous coronary intervention and coronary artery
bypass grafting). MI was defined according to international
guidelines http://www.escardio.org. IHD was defined as a
previous episode with increased plasma coronary markers,
ECG verified MI or previous coronary revascularization.
All patients with IHD in the study had been referred
to a myocardial perfusion imaging if they were consid-
ered to have an intermediate risk of having coronary
artery disease (CAD) (symptoms of transient chest pain
and/or worsening of chest pain when exercising and/or
transient referred pain to the upper limbs or neck) or
had a history of CAD with renewed suspicion of ische-
mia. All patients had an abnormal myocardial perfusion.
All other patients in the study were without symptoms
of cardiovascular disease and had a normal resting ECG.
Measurements
Analyses of the following markers of inflammations
were performed: 1) Human MGP (mAb
3-15) was mea-
sured using an ELISA (Biomedica Medizinprodukte,
Vienna, Austria). Standard range was 0-90 nmol/l, lower
detection limit was 0.3 nmol/l and intra- and interassay
coefficients of variation were 5.5% and 8.0%, respec-
tively. 2) Plasma YKL-40 was measured using an ELISA
method (Quidel, USA). Measuring range was 20-300 ng/
ml, with intra- and interassay coefficients of variation of
5.8% and 6.0%, respectively. 3) CRP was measured with
a highly sensitive, latex-particle-enhanced immunoturbi-
dimetric assay (DAKO, Glostrup, Denmark) with a mea-
suring range of 0.2-80 mg/l and a lower detection limit
of 0.03 mg/l.
Statistical analyses
Following a test of statistical (log-) normality, data are
presented as mean ± SD or as median and interquartile
range (IQR). Comparisons between the groups were per-
formed by a One-Way ANOVA. A non-parametric test
was used if a variable exhibited a clear non-Gaussian
distribution. The c2-test was used for categorical vari-
ables. Analyses of associations were performed in the
total study population using linear regression models
with MGP, YKL-40 or hsCRP as dependent variable.
Univariate analyses of correlations of either one of the
biomarkers YKL-40, hsCRP and MGP were performed
prior to multivariate analyses. Multivariate analyses
including age, gender, patient category, cholesterol
levels, blood pressure, and presence of IHD or diabetes
were performed for biomarkers with significant outcome
in the univariate analyses. All p-values were calculated
as two-sided, and a p-value < 0.05 was considered
significant.
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age SPSS15.0 (SPSS inc., Chicago, Il, USA).
Results
Clinical data
Clinical characteristics of the different patient categories
of the study population are presented in Table 1. There
was an equal distribution between genders. Patients with
T2D without IHD and the control subjects were
younger that patients with IHD (p < 0.001). There was a
significant difference in systolic but not in diastolic
blood pressure between groups and more patients with
both T2D and IHD had hypertension. Significantly
lower levels of LDL-cholesterol and higher levels of
HDL-cholesterol were found in patients with IHD when
compared to patients without IHD (p < 0.0001).
Patients with IHD were more frequently treated with
ACE inhibitors, beta blockers (BB), statins and diuretics
as compared to T2D patients without IHD (p < 0.001
for ACE, BB and statins; p = 0.002 for diuretics).
Markers of calcification and inflammation
MGP
MGP levels were significantly higher in patients with
both T2D and IHD, when compared to patients with
either IHD or T2D (p < 0.001 for all comparisons)
(Table 2). Moreover, MGP levels in non-diabetic
patients with IHD were higher than in T2D patients
without IHD (p = 0.007) (Figure 1a). Univariate ana-
lyses revealed significant correlations between MGP
and age (r = 0.43), HDL- and LDL-cholesterol levels
(r = 0.59 and r = -0.47, respectively), LDL:HDL-
cholesterol ratio (r = -0.62), statin (r = 0.55) and ACE
treatment (r = 0.47) and patient category (r = 0.73)
(all p ≤ 0.001) (Table 3). A similar pattern was found
in subgroup analyses of patients with either IHD only
or T2D only. No correlation was found between MGP
levels and serum creatinine levels (r = -0.27, p =
0.45). In the total group of control subjects and IHD
patients without T2D, MGP correlated positively with
hsCRP (r = 0.50, p < 0.0001) and YKL-40 (r = 0.30;
p = 0.03), whereas it correlated negatively to hsCRP
in the total group of T2D patients without and with
IHD (r = -0.28, p = 0.03). In multiple linear regres-
sion analyses MGP was associated with patient cate-
gory (r = 0.36, p < 0.001), and HDL-cholesterol levels
(r = 0.29, p < 0.001) adjusting for the significant
covariates.
Levels of MGP were significantly higher in patients
treated with statins (2.32 ± 0.37 vs. 1.83 ± 0.41, p <
0.001) and ACE-inhibitors (2.36 ± 0.43 vs. 1.95 ± 0.43,
p < 0.001) compared to non-treated.
Table 1 Clinical characteristics of the study population
Control
subjects
Patients
with T2D
Patients
with IHD
Patients with
T2D and IHD
P-value
Between groups
N2 0 4 5 3 7 2 0
Male (%) 6 (30) 22 (49) 9 (24) 9 (45) 0.1
Age (yrs); range 50 (34-66) 54 (41-73) 66 (47-81) 63 (47-79) <0.001
Weight (kg) 81,5 ± 14,1 85,1 ± 12,2 82,9 ± 14,6 84,5 ± 15,5 0.57
Body mass index (kg/m
2) 26,3 ± 3,6 29,5 ± 3,8 28,2 ± 5,5 29,7 ± 5,2 0.02
Duration diabetes (yrs)* - 2 (0-15) - 8 (3-26) <0.001
Diastolic BP (mmHg) 81 ± 8 84 ± 11 87 ± 13 83 ± 10 0.34
Systolic BP (mm Hg) 131 ± 11 141 ± 19 145 ± 25 150 ± 23 0.045
Hypertension (%) 0 14 (31) 9 (24) 13 (65) <0.001
MI (%) - - 26 (70) 8 (40)
PCI/CABG (%) - - 27 (73) 11 (55)
Total cholesterol (mM) 5,3 ± 1,0 5,7 ± 1,3 4,9 ± 1,3 5,0 ± 1,2 0.026
LDL-cholesterol (mM) 3,8 ± 0,9 4,0 ± 1,3 2,7 ± 1,1 2,5 ± 0,8 <0.001
HDL-cholesterol (mM) 0,89 ± 0,30 0,80 ± 0,41 1,34 ± 0,48 1,27 ± 0,26 <0.001
Creatinine (μM) NA 82 ± 21 90 ± 22 94 ± 31 0.23
ACE (%) - 13 (27) 18 (49) 15 (71) <0.001
BB (%) - 7 (15) 29 (78) 12 (57) <0.001
CCB (%) - 5 (10) 7 (19) 5 (24) 0. 1
Statins (%) - 21 (43) 31 (84) 18 (86) 0.004
Diuretics (%) - 13 (27) 15 (41) 11 (52) 0.002
NTG (%) - - 13 (35) 5 (24) <0.001
*Median (range); Mean ± SD; Number (%); NA Not analysed
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Levels of YKL-40 were significantly higher in patients
with IHD and T2D (p < 0.05) (Figure 1b)). However,
levels of YKL-40 did not differ between patients with
both T2D and IHD and the control group (p = 0.1). No
differences were seen in levels of YKL-40 between
patient treated with statins (p = 0.13) and ACE-inhibi-
tors (p = 0.20) (data not shown) when compared to
non-treated patients.
Only patient category (r = 0.22, p = 0.04) and LDL:
HDL-cholesterol ratio (r = 0.31, p = 0.02) was signifi-
cantly associated with levels of YKL-40 in a multiple
regression model adjusting for the significant covariates.
CRP
Levels of hsCRP were significantly higher in any patient
group when compared to the control group (p ≤ 0.001
for all comparisons) (Figure 1c). Patients with T2D but
no IHD had significantly higher levels of hsCRP com-
pared to patients with IHD (p = 0.008), but not com-
pared to patients with T2D and IHD (p = 0.16). No
differences were seen in levels of hsCRP between patient
treated with statins (p = 0.14) and ACE-inhibitors (p =
0 . 8 6 )( d a t an o ts h o w n )w h e nc o m p a r e dt on o n - t r e a t e d
patients.
In a multiple regression analysis hsCRP was only asso-
ciated with BMI (r = 0.42, p < 0.001) after adjusting for
the significant covariates.
None of the biomarker levels differed between genders
(p > 0.4).
Discussion
The present study is to our knowledge the first to com-
pare MGP expression in patients with either T2D or
IHD or both. We describe increased serum MGP levels
in patients with either T2D or IHD as well as in patients
with both T2D and IHD, when compared to healthy
control subjects. Significantly higher levels of MGP were
found in patients with IHD when compared to patients
without IHD, while no difference was seen when com-
paring patients with and without T2D. A stepwise
increase was seen in serum MGP, with the highest levels
in patients with both T2D and IHD. Based on our
results it seems as if increased MGP not only is a mar-
ker of IHD characterized by intima calcification and
subsequent atherosclerosis, but also of media sclerosis
as typical seen in diabetes since an apparent additive
concentration of MGP are documented in patients with
both T2D and IHD. As in a previous study, we also
found associations of MGP concentrations with levels of
HDL- and LDL- cholesterol, consistent with the evi-
dence that traditional lipid risk factors are significantly
associated with circulating MGP [13].
Atherosclerosis and vascular calcification are extre-
mely complex mechanism, with a long list of potential
derangements on different pathways, and biomarkers
have been extensively evaluated and become an impor-
tant tool, helping to improve patient care [16]. Novel
biomarkers of vascular inflammation, atherosclerosis
and calcification and advanced glycation have been asso-
ciated with both macrovascular late complications in
high-risk T2D patients and with the severity of athero-
sclerosis in patients with carotid artery disease and
lower limp artery disease [16-20].
In individuals without compromised kidney function
as in the present study, levels of circulating MGP
depend primarily on the synthesis and secretion and
clearance of MGP from VSMC and subsequent binding
of MGP to calcified areas within the vascular wall. We
found significantly increased levels of serum MGP in
patients with T2D and in patients with IHD, when com-
pared to healthy control subjects, which is in agreement
with previous studies demonstrating increased serum
MGP levels in patients with severe atherosclerosis and
in patients with type 1 diabetes [13]. We found an addi-
t i v ee f f e c to fT 2 Da n dI H Do nM G Pl e v e l s ,w h i c hh a s
never been demonstrated previously. This effect is prob-
ably due to a more advanced and general cardiovascular
disease in patients with both T2D and IHD, when com-
pared to patients with either T2D or IHD. Furthermore,
MGP levels were significantly higher in non-diabetic
patients with IHD compared to patients with T2D with-
out clinical IHD, implying that the calcification process
seems more active in conditions with clinical athero-
sclerosis, but obviously also active in conditions with
increased risk of media and intima calcification as in
T2D when compared to healthy subjects.
It is also well known that the risk of myocardial infarc-
tion (MI) is similar in T2D patients without prior MI and
in non-diabetic patients with prior MI, and that the risk
is even higher in diabetic patients with previous MI [21].
Table 2 Biomarkers
Control
subjects
Patients
with T2D
Patients
with IHD
Patients with
T2D and IHD
P-value
Between groups
MGP (nmol/l) 5,4 (4,5-6,3) 6,1 (5,2-7,1) 9,7 (9,1-10,7) 14,2 (12,7-15,9) <0.001
YKL-40 (ng/ml) 42 (31-72) 61 (47-133) 63 (51-110) 69 (43-184) = 0.02
hsCRP (mg/l) 1,1 (0,5-1,7) 6,3 (3,2-10,9) 2,3 (1,3-3,9) 2,6 (1,9-3,6) <0.001
Median (IQR)
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intima where it is associated with atherosclerosis and in
t h et u n i c am e d i aa sM ö n c k e b e r g ’s sclerosis [22]. Media
sclerosis is most commonly seen in patients with diabetes
where it develops independent of atherosclerosis, imply-
ing different etiological mechanisms. Media calcifications
are associated with VSMCs, whereas intima calcification
in atherosclerosis occurs in macrophage and lipid rich
atherosclerotic lesions. VSMCs grown in culture contain
high levels of MGP, which is thought to limit the rate of
calcification. MGP is a strong local inhibitor of vascular
calcification, and although circulating MGP has no
known biological function [12], it may reflect inhibition
of calcification processes in the vascular wall. In healthy
vessels MGP is synthesized at a low rate, probably
because the need for calcification inhibition is low [9,23].
In vessels from patients withd i a b e t e s ,M G Pl e v e l sa r e
lower than in normal vessels, which suggest that reduced
MGP in diabetes may predispose to calcification [24].
However, levels of MGP has been demonstrated to be
high in calcified vessels, where MGP most probably is
expressed as an inhibitory counteraction of the calcifica-
tion process [6,23].
Inflammation is probably an initial event very early on in
plaque formation leading to calcification and IHD [25]. It
has been demonstrated that statins, through their capacity
to inhibit inflammation, can reduce the increased osteo-
genic and inflammatory activities seen with plaque pro-
gression, and this is correlated with the reduction in
calcification [26]. In the present study we found that
significantly more patients with IHD were treated with sta-
tins, so we cannot exclude that this has influenced the
levels of MGP. However, since statin treatment reduces
inflammation and can ameliorate the calcification response
in the vessel wall, higher MGP levels would be expected
had the patients been without statin treatment.
Taken together, our and previous studies suggest that
arterial calcification may lead to increased MGP expres-
sion, probably in a feedback attempt to reduce bone-like
formation of calcium deposits in the vessel walls. How-
ever, it is still unclear whether serum MGP levels reflect
activation, tissue production and deposition.
Several studies have documented, that low-grade
inflammation and activation of the innate immune sys-
tem is involved in the common pathogenesis to athero-
sclerosis, endothelial dysfunction, insulin resistance and
the development of T2D. We found significantly
increased YKL-40 concentrations in patients with either
T 2 Da n d / o rI H D ,t h u sc o n f i r m i n gp r e v i o u ss t u d i e s
[27-30]. We also found a correlation between YKL-40
and patient category. As in a previous study of patients
with T2D [27,28], no correlation was found between
hsCRP and YKL-40 implying, that YKL-40 and CRP are
produced and secernated independently of each other.
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Figure 1 Levels of MGP, YKL-40 and hsCRP were significantly
different between the groups (ANOVA, *0.0001 < p < 0,01 for
all comparisons) (-T2D/-IHD N = 20; +T2D/-IHD N = 45; -T2D/
+IHD N = 37; +T2D/+IHD N = 20). MGP levels were significantly
higher in patients with both T2D and IHD when compared to the
other groups (+p < 0.001 for all comparisons), and in IHD patients
when compared to patients with T2D and controls (#p ≤ 0.007).
Levels of YKL-40 were significantly higher in patients with T2D and
in patients with IHD when compared to the control subjects (p <
0.03). Levels of hsCRP were significantly higher in patients with T2D
with and without IHD when compared to the control group (+p ≤
0.001 for all).
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are independently associated with the presence and
extent of CAD [29-32]. In patients with myocardial
infarction even higher YKL-levels are documented [31].
YKL-40 has also been found to be associated with all-
cause as well as cardiovascular mortality in both patients
with stable IHD [31] and in the general population
above 50 years of age without known diabetes or IHD
[28]. In patients with type 1 diabetes, increasing levels
of YKL-40 are seen with increasing levels of albumi-
nuria, suggesting that YKL-40 might be able to be used
as an early marker of CVD [33]. The present finding
seems to support this hypothesis.
It is well-known that serum CRP is increased in T2D
patients [1]. We found a 7-fold higher concentration of
serum hsCRP among T2D patients without IHD and a 3-
fold higher in T2D patients with IHD, when compared to
healthy control subjects. Furthermore, we found a strong
correlation between serum hsCRP and BMI and patient
category. It is also well known that CRP is a cardiovascu-
l a rm a r k e re v e nw i t h i nr a n g e sc o n s i d e r e dn o r m a l
[ 3 4 - 3 6 ] .I nt h ep r e s e n ts t u d yw ef o u n dan e a r l y4 - f o l d
higher concentration of serum hsCRP in non-diabetic
patients with IHD together with a strong correlation
between serum hsCRP and BMI and HDL-cholesterol
levels, in patients with and without IHD. Levels of hsCRP
were significantly lower in non-diabetic patients with
IHD compared to patients with T2D without IHD. Based
on our and previous studies it can be speculated, that the
low grade inflammation seen in both IHD and T2D
declines in diabetes, when diabetic patients develop
symptomatic atherosclerosis, and therefore make hsCRP
as a biomarker of IHD in diabetic patients questionable.
In the present study, more patients with IHD received
statin treatment. Statins inhibit inflammation, and early
treatment of inflammation seems to ameliorate the cal-
cification response in the vessel wall [26]. We found
increased levels of the inflammatory markers YKL-40
and hsCRP in patients with T2D and IHD, when com-
pared to control subjects, however no differences were
found in levels of these inflammatory markers between
statin treated and non-treated patients. Statin treatment
in especially IHD patients could also influence the levels
of both YKL-40 and hsCRP, but without this treatment
we would expect even higher levels of both markers in
the IHD groups. In a recent study of patients with stable
coronary artery disease (CAD), it was shown that YKL-
40 levels were significantly reduced in statin treated
patients compared to non-treated patients [37]. The
median YKL-40 levels were 77% higher in the non-trea-
ted CAD group compared to the non-treated patients in
our study, and median YKL-40 levels in statin treated
CAD group were comparable to our statin treated
patients, so we do not think that the participants in the
two studies are comparable.
We found that patients treated with statins had higher
levels of MGP, and since we also found a positive corre-
lation between HDL levels and MGP and a negative cor-
relation between LDL levels and MGP, it could be
speculated that higher MGP levels were an indication of
better clinical and prognostic regulation of lipid levels
due to statin treatment. Higher MGP levels could there-
fore be a positive indicator for the prognosis due to its
function as an inhibitor of medial calcification of
arteries. In a multiple regression analyses there were
however no association between MGP levels and statin
use or LDL-levels, adjusting for significant covariates,
but we do not now if MGP can be used as a biomarker
or positive indicator for prognosis of IHD.
In conclusion, in patients with T2D and IHD we
found increased levels of plasma MGP which may indi-
cate progressing media and intima calcification pro-
cesses. Moreover, these processes were paralleled by
increased inflammation, which may reflect an initial
event very early on in the processes leading to
calcification
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